SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Celularity Inc. (CELU) has a negative trailing P/E of -0.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.9 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -219.41%, forward earnings yield 114.94%.
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+130.8%).
- Forward P/E 0.9 — analysts expect a return to profitability with estimated EPS of $1.50 for FY2027.
- Trailing Earnings Yield -219.41% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 114.94% as earnings recover.
- Analyst consensus target $3.00 (+130.8% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 44/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CELU
Valuation Multiples
P/E (TTM)-0.5
Forward P/E0.9
PEG RatioN/A
Forward PEGN/A
P/B Ratio-1.83
P/S Ratio0.83
EV/EBITDA-1.6
Per Share Data
EPS (TTM)$-3.06
Forward EPS (Est.)$1.50
Book Value / Share$-0.76
Revenue / Share$1.54
FCF / Share$-0.25
Yields & Fair Value
Earnings Yield-219.41%
Forward Earnings Yield114.94%
Dividend Yield0.00%
Analyst Target$3.00 (+130.8%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2018 |
-320,753.6 |
0.00 |
-2,798.54 |
20.06 |
- |
| 2019 |
-1.1 |
0.00 |
1.72 |
11.23 |
- |
| 2020 |
-1.0 |
-0.04 |
10.83 |
14.19 |
- |
| 2021 |
-3.4 |
0.04 |
3.45 |
16.09 |
- |
| 2022 |
12.7 |
-0.12 |
0.91 |
10.04 |
- |
| 2023 |
-0.2 |
0.00 |
1.07 |
1.93 |
- |
| 2024 |
-0.8 |
0.01 |
5.15 |
0.84 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$0.00 |
$17.55M |
$-1.1K |
-0% |
| 2019 |
$2.46 |
$21.15M |
$5.88M |
27.8% |
| 2020 |
$-17.00 |
$14.28M |
$-208.23M |
-1458.4% |
| 2021 |
$-14.90 |
$21.34M |
$-100.12M |
-469.3% |
| 2022 |
$0.95 |
$17.98M |
$14.19M |
79% |
| 2023 |
$-11.02 |
$22.77M |
$-196.3M |
-862% |
| 2024 |
$-2.64 |
$54.22M |
$-57.89M |
-106.8% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-2.75 |
$-2.75 – $-2.75 |
$44M |
$44M – $44M |
1 |
| 2027 |
$1.50 |
$1.50 – $1.50 |
$285.66M |
$285.66M – $285.66M |
1 |
